Shenzhen Ionova Life Sciences Co., Ltd.

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
CDK2/CDK4Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 1/2
KRAS G12DSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
February 2028 (1)
INV-6452Phase 1/2Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian Cancer …
Est. primary completion 2028-02-04 · NCT07612891 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
INV-8989Phase 1/2Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic …
Est. primary completion 2029-05 · NCT07610798 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.